Sudeep Pharma has made an impressive debut on the stock market, with shares soaring shortly after their listing on November 28, 2025. The company’s stock opened at ₹733.95 on the Bombay Stock Exchange (BSE), reflecting a 23.7% premium over its initial public offering (IPO) price of ₹593. On the National Stock Exchange (NSE), shares began trading at ₹730, also indicating a 23% premium.
The strong opening follows a highly successful IPO, which saw subscriptions nearly 94 times, driven largely by substantial institutional interest. By the end of the bidding, the IPO had garnered a subscription rate of 93.72 times.
Market expert Shivani Nyati, Head of Wealth at Swastika Investmart Ltd., advised investors to implement a disciplined stop-loss at ₹690. This strategy is intended to safeguard against potential losses as the stock begins trading.
At 11:38 AM, Sudeep Pharma’s share price had surged to ₹793.35 on the BSE, eliciting congratulations from various market observers, including a public acknowledgment from NSE India. The stock’s stellar performance showcases the robust demand surrounding the IPO, which had been heavily oversubscribed prior to its launch.
During the early trading session, the broader market showed mixed signals, with the Sensex declining by 97.59 points to 85,622.79 and Nifty dropping by 22.70 points to 26,192.85. However, Sudeep Pharma’s successful listing provided a bright spot amid the overall market dynamics.
For those tracking the performance of the stock, further updates and insights are available on financial news platforms, including real-time tracking of share prices and market reactions.
